¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"calcium channel blocking agent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® calcium ÇÑ±Û Ä®½·
¼³¸í   
  ½ÅüÀÇ °ÅÀÇ ¸ðµç Á¶Á÷¿¡¼­ ¹ß°ßµÇ´Â ÀüÇØÁú·Î ¿©·¯ °¡Áö ¿ªÇÒÀ» ¸ö¿¡¼­ ´ã´çÇÑ´Ù. Áß¿äÇÑ ±â´ÉÀ» »ìÆìº¸¸é ¿ì¼± Àλê°ú °áÇÕÇÏ¿© »À³ª ÀÌ»¡À» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù. ±×¸®°í ¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡ ¾ø¾î¼­´Â ¾ÈµÉ ÀüÇØÁú·Î ÀÛ¿ëÀ» ÇÑ´Ù. Ç÷¾×ÀÀ°íÀÇ ¿©·¯ ´Ü°è¿¡µµ °ü¿©ÇÑ´Ù.
¿µ¹® cardiotonic, cardiotonic agent ÇÑ±Û °­½ÉÁ¦
¼³¸í   
  ½ÉÀåÀÇ ¼öÃà·ÂÀ» Áõ°¨½Ã۴ ¾à¹°À» ¸»ÇÑ´Ù. ±âº»ÀûÀ¸·Î ½É±Ù¼öÃà·ÂÀ» Áõ°­½ÃÄÑ ½ÉÀå¹ÚÃâ·®À» Áõ°¡½Ã۴ ¾à¹°ÀÌ´Ù. °­½É¹è´çü, Æ÷½ºÆ÷µð¿¡½ºÆ®¶ó¾ÆÁ¦ ¾ïÁ¦Á¦, ¾Æµå·¹³¯¸° ¥â¼ö¿ëüÀÛ¿ëÁ¦, Ç÷°üÈ®ÀåÁ¦ µîÀÌ ÀÖ´Ù. ´ëÇ¥ÀûÀΠ¿¹·Î¼­´Â µð°î½Å(digoxine) µîÀÇ µðÁöÅ»¸®½º(digitalis)°¡ ÀÖ´Ù.
¿µ¹® alkylating agent ÇÑ±Û ¾Ëųȭ¾à¹°
¼³¸í   
  Ç×¾ÏÁ¦ÀÇ ÀÏÁ¾. ÀÌ»óÀûÀΠÇ×¾ÏÁ¦´Â Á¤»óÀûÀΠ¼¼Æ÷¿¡´Â Çظ¦ ÁÖÁö ¾Ê°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀΠȿ°ú¸¦ ³ªÅ¸³»¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀǠƯÀÌÇѠƯ¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇϴ ¾à¹°À» °³¹ßÇØ¾ß ÇÑ´Ù. ÇöÀç ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº ´Ù½Ã ¸»Çϸé À¯Àü Á¤º¸¸¦ °¡Áö°í Àִ DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼­ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼­µµ Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â Á¤»óÀûÀΠ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒÈ­°üÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î À̵頼¼Æ÷µµ ÇÔ²² Ä¡¸íÀûÀΠ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼­ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒÈ­ºÒ·®ÀÌ Àß ¿Â´Ù). ¾ËĮȭ¾à¹°ÀÇ °æ¿ì¿¡´Â DNA¿Í Á÷Á¢ °áÇÕÀ» ÇÏ¿© DNAÀÇ º¹Á¦¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á Ç×¾ÏÁ¦ÀÇ ¿ªÇÒÀ» ¼öÇàÇÑ´Ù.
¿µ¹® anti-inflammatory agent ÇÑ±Û Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
¼³¸í   
  ±¹¼Ò¿¡ ÀÛ¿ëÇÏ¿© ¿°ÁõÀ» Ä¡·áÇÏ°í ¹æÁöÇϴ ¾à. ¿°ÁõÀ» °¡¶ó¾ÉÈ÷´Â ¾àÀ» ¸»ÇÑ´Ù. Á¶Á÷À» ±äÃà-Ä¡¹ÐÇϰԠÇÏ¿© Àå¾×°ú Á¡¾×ÀÇ ºÐºñ¸¦ ÁÙÀ̰í, Ç¥¸é¿¡ Àִ ÀÛÀº Ç÷°ü¿¡ ºóÇ÷À» ÀÏÀ¸ÄÑ ÃæÇ÷µÇ´Â °ÍÀ» ¹æÁöÇÔÀ¸·Î½á ¿°ÁõÀû º´º¯À» Á¦°ÅÇÏ¿© ¸ðµç Áõ¼¼¸¦ ¾ø¾Ø´Ù. ´ëºÎºÐÀÇ ¼ö·ÅÁ¦-¿ÏÈ­Á¦-Áø¾çÁ¦°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. Áß¿äÇÑ ¼ººÐÀ¸·Î´Â ¾Ë·ç¹Ì´½-ºñ½º¹«Æ®-¾Æ¿¬-³³È­ÇÕ¹°(º´¹Ý-Æä¸£¸¶Åç-¾Æ¿¬È­-¿¬´ç µî) µîÀÌ ÀÖ´Ù. ÀÛ¿ë¿¡ µû¶ó Ç׿°ÁõÁøÅëÁ¦¿Í Ç׿°ÁõÈ¿¼ÒÁ¦·Î ³ª´¶´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium-channel blocker
    Ä®½·Åë·ÎÂ÷´ÜÁ¦
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • blocking agent
    Â÷´ÜÁ¦
  • cholinergic blocking agent
    Äݸ°Â÷´ÜÁ¦
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦
  • blocking antibody
    Â÷´ÜÇ×ü
  • blocking of thought
    »ç°íµÎÀý
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • coronary calcium scan
    °ü»óµ¿¸ÆÄ®½·½ºÄµ
  • calcium
    Ä®½·
  • calcium chloride
    ¿°È­Ä®½·
  • calcium ethylenediaminetetraacetic acid
    Ä®½·¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • calcium gluconate
    ±Û·çÄÜ»êÄ®½·
  • calcium oxalate stone
    ¼ö»êÄ®½·µ¹
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blocking agent
    Â÷´ÜÁ¦
  • channel
    Åë·Î
  • sodium channel
    ³ªÆ®·ýÅë·Î
  • blocking antibody
    Â÷´ÜÇ×ü
  • calcium ethylenediaminetetraacetic acid
    Ä®½·¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • calcium
    Ä®½·
  • calcium gluconate
    ±Û·çÄÜ»êÄ®½·
  • blocking of thought
    »ç°íµÎÀý
  • agent
    1. ¾à¹°, ¾àÁ¦, 2. ¹°Áú, 3. ÀÎÀÚ
  • alkylating agent
    ¾Ëųȭ¾à¹°, ¾ËųȭÁ¦
  • anti-inflammatory agent
    Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
  • antiasthmatic agent
    Ç×õ½ÄÁ¦
  • antifungal agent
    Ç×Áø±ÕÁ¦
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
  • antitumor agent
    Ç×¾ÏÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´ÜÁ¦
  • blocking agent
    Â÷´ÜÁ¦
  • cholinergic blocking agent
    Äݸ°Â÷´ÜÁ¦
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦
  • calcium
    Ä®½·
  • calcium chloride
    ¿°È­Ä®½·
  • calcium oxalate stone
    ¼ö»êÄ®½·µ¹
  • calcium phosphate stone
    ÀλêÄ®½·µ¹
  • calcium-catalyzed reaction
    Ä®½·Ã˸ŹÝÀÀ
  • blocking antibody
    Â÷´ÜÇ×ü
  • blocking test
    Â÷´Ü½ÃÇè
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø½Å°æ±ÙÂ÷´ÜÁ¦
  • ganglionic blocking drug
    ½Å°æÀýÂ÷´Ü¾àÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦.
  • receptor blocking agent
    ¼ö¿ëüÂ÷´Ü<ºÀ¼â>Á¦.
  • Fast channel
    ±Þ¼Ó(ÐááÜ)Åë·Î(÷×ÖØ)
  • T-type channel
    T-Çü Åë·Î
  • acetylcholine channel
    ¾Æ¼¼Æ¿Äݸ° Åë·Î
  • hepatocardiac channel
    °£½ÉÀå__ÊÜãýíôϵ).
  • porin channel
    Æ÷¸°Åë·Î
  • potassium channel
    Ä®·ýÅë·Î
  • pyloric channel
    À¯¹®Åë·Î.
  • Ganglionic blocking drugs
    ½Å°æÀýÂ÷´Ü¾àÁ¦(ãêÌèï½ó´Ó¨å·ð¥)
  • H2 recepor blocking agents, for ulcers
    H2¼ö¿ëüÂ÷´ÜÁ¦(â¥é»ô÷ó´Ó¨ð¥)
  • alpha blocking
    ¾ËÆÄÂ÷´Ü
  • antibody, blocking
    Â÷´ÜÇ×ü
  • ganglionic blocking action
    ½Å°æÀýÂ÷´ÜÀÛ¿ë.
  • genetic blocking
    À¯ÀüÀû Â÷´Ü(ë¶îîîÜó´Ó¨).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • calcium channel
    Ä®½·Åë·Î( -÷×ÖØ).
  • calcium channel
    Ä®½· Åë·Î(÷×ÖØ)
  • calcium channel antagonist,blocker
    Ä®½·Åë·Î ±æÇ×Á¦( -÷×ÖØ ÑÏù÷ð¥),Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦.
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°(¼º) ºÀ¼â<Â÷´Ü>¾à.
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´Ü<ºÀ¼â>Á¦(í»ëÏãêÌèó´Ó¨<Üæáð>ð¥).
  • blocker/blocking agent
    Â÷´ÜÁ¦
  • blocking agent
    Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • cholinergic blocking agent
    Äݸ°¼ºÂ÷´ÜÁ¦
  • cholinergic blocking agent
    Ç×Äݸ°¼º¾à(ù÷¡­å·), Äݸ°¼º Â÷´Ü<ºÀ¼â>Á¦.
  • competitive blocking agent
    °æÀZ(Ìæî³àõ) Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • competitive blocking agent
    °æÇÕ¼º Â÷´ÜÁ¦.
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antiprotozoal agent
    Ç׿øÃæÁ¦
  • calcium folinate
    Ä®½·Æú¸®³×ÀÌÆ®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
  • blocking group
    Â÷´Ü±â(ó´Ó¨Ðñ)
  • channel
    "ä³Î, Åë·Î(÷×ÖØ)"
  • channel protein
    ä³Î ´Ü¹éÁú(Ó±ÛÜòõ)
  • gated channel
    °ü¹® Åë·Î (μڦ÷×ÖØ)
  • ion channel
    À̿ Åë·Î(÷×ÖØ)
  • ligand-gated channel
    ¸®°£µå °ü¹®Åë·Î(μڦ÷×ÖØ)
  • voltage-gated channel
    Àü¾Ð°³Æó(ï³äâËÒøÍ) Åë·Î(÷×ÖØ)
  • calcium
    Ä®½·
  • calcium-activated factor
    Ä®½·ºÎȰ ÀÎÀÚ(Ý·üÀì×í­)
  • calcium-activated neutral proteinase
    Ä®½·ºÎȰ(Ý·üÀ) Áß¼º(ñéàõ)ÇÁ·ÎƼ³×À̽º
  • calcium chloride transformation
    ¿°È­Ä®½· º¯Çü¼ú(ܨû¡âú)
  • calcium-dependent proteinase
    Ä®½·ÀÇÁ¸(ëîðí) ÇÁ·ÎƼ³×À̽º
  • calcium-dependent regulatory protein
    Ä®½·ÀÇÁ¸ Á¶Àý´Ü¹éÁú(ëîðíðàï½Ó±ÛÜòõ)
  • calcium phosphate gel
    Àλê(×òß«)Ä®½· Á©
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium
    Ä®½·
  • calcium, milk
    Ä®½·¿ìÀ¯
  • milk of calcium
    ¿ìÀ¯ÇüÄ®½·
  • milk of calcium bile
    ¿ìÀ¯ÇüÄ®½·´ãÁó
  • channel
    Åë·Î
  • collateral channel
    °çÅë·Î, ºÎÇà·Î
  • hepatocardiac channel
    °£½ÉÀ屸
  • lymph channel
    ¸²ÇÁ°ü
  • parallel channel sign
    ÆòÇà°ü¡ÈÄ
  • signal channel
    ½ÅÈ£Åë·Î
  • agent
    ¾à¹°, ÀÛ¿ë¹°Áú, º´ÀÎ
  • alkylating agent
    ¾ËųȭÁ¦, ¾Ëųȭ¾à¹°
  • anabolic agent
    µ¿È­¾à¹°
  • antitumor agent
    Ç׾Ͼà, Á¦¾Ï¾à
  • bleaching agent
    Ç¥¹éÁ¦
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NMB neuromedin B; neuromuscular blockade; neuromuscular blocking; neuromuscular blocker/blocking [drug, ...
SBF serologic-blocking factor; specific blocking factor; splanchnic blood flow
GBA ganglionic blocking agent; gingivobuccoaxial
NMBA neuromuscular blocking agent
Ca2+-blocker calcium channel blocker
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NMBA Neuromuscular blocking agent
KATP channel ATP sensitive potassium channel
BK channel K channel
CRC Calcium Release Channel
CCA Calcium channel antagonists
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • channel tray ºÐÇÒ º¹À§½Ä ¸ðÇüÀ» Á¦ÀÛÇÒ ¶§ »ç¿ëµÇ´Â ÇÃ¶ó½ºÆ½ ʹÝ. Dilok tray¿Í °°Àº ±â´ÉÀ» ÇÏ´Â °ÍÀÌ´Ù.

    channel-shoulder-pin attachment

    ¾¾ ¿¡½º ÇÇ ºÎ°¡ ÀåÄ¡
    Ä¡°ú ±â°ø½Ç¿¡¼­ Á¦ÀÛÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î °¢Á¾ Àΰø Ä¡°ú
  • calcium channel
    Ä®½· ä³Î
    Ä®½·ÀÌ Åë°úÇÏ´Â µµ°ü.
  • calcium channel blocker
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°, Ä®½· ä³Î Â÷´ÜÁ¦
    µ¿ÀǾî=calcium channel blocking drug. 1. Ä®½·ÀÌ Åë°úÇÏ ´Â µµ°üÀ» ¸·´Â ¾à¹°. 2. Ç× Çù½ÉÁõ Á¦Á¦, Ç×°íÇ÷¾Ð Á¦Á¦, Ç× ºÎÁ¤¸Æ Á¦Á¦·Î »ç¿ëµÇ´Â ¾à¹°·Î½á, µ¿¸ÆÀÇ ÆòȰ±Ù¿¡¼­ Ä®½·ÀÇ À¯ÀÔÀ» Â÷´ÜÇÔÀ¸·Î½á ¸»ÃÊ ¼Òµ¿¸ÆÀ» ÀÌ¿ÏÇØ¼­ ½É±ÙÀÇ »ê¼Ò ¿ä±¸·®À» ÀúÇϽÃŰ´Â ±â´ÉÀ» ÇÑ´Ù. ´ëÇ¥ÀûÀÎ ¾à¹°·Î´Â, vera
  • calcium-channel blocker
    Ä®½· Â÷´ÜÁ¦, Ä®½· Åë·Î Â÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸° Â÷´ÜÁ¦
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¿¡ ÀÛ¿ëÇÏ¿© ½Å°æ Àü´Þü¿Í ¼ö¿ëü°¡ °áÇÕÇÏÁö ¸øÇÏ°Ô ÇÔÀ¸·Î½á ±³°¨½Å°æ ÈïºÐ È¿°ú¸¦ ºÀ¼âÇÏ´Â ¾à¹°.
  • autonomic blocking agent
    ÀÚÀ² ½Å°æ Â÷´ÜÁ¦
  • beta-adrenergic blocking agent
    º£Å¸ ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • cholinergic blocking agent
    Ç×Äݸ°¾à, Äݸ°¼º Â÷´ÜÁ¦
  • neuromuscular blocking agent
    ½Å°æ±Ù Â÷´ÜÁ¦, ½Å°æ±Ù Â÷´Ü ¾à
  • receptor blocking agent
    ¼ö¿ëü Â÷´ÜÁ¦
  • sympathetic blocking agent
    ±³°¨½Å°æ ºÀ¼âÁ¦, ±³°¨½Å°æ Â÷´ÜÁ¦
  • channel block
    Åë·Î Â÷´Ü
  • collateral channel
    °çÅë·Î, ºÎÇà·Î
  • ion channel
    À̿ Åë·Î
    ¼¼Æ÷¸· µî¿¡ Á¸ÀçÇϸç ÀÚ±ØÀÌ ¿À¸é Åë·Î¸¦ ¿­°í, ´ÝÀ½À¸·Î ÇØ¼­ ÀÌ¿ÂÀÇ ³óµµ¸¦ Á¶ÀýÇØ¼­ ÀÚ±ØÀÇ Àü´Þ¿¡ °ü¿©ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
slow channel-blocking agent calcium channel-blocking agent
adrenergic blocking agent A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's.
(05 Mar 2000)
adrenergic neuronal blocking agent A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines.
(05 Mar 2000)
alpha-adrenergic blocking agent An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension.
Synonym: alpha-blocker.
(05 Mar 2000)
beta-adrenergic blocking agent A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
beta-adrenergic receptor blocking agent A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
blocking agent A class of drugs that inhibit (block) a biologic activity or process, such as axonal conduction or transmission, or ions across a cell membrane; frequently called "blockers."
(05 Mar 2000)
ganglionic blocking agent An agent that impairs the passage of impulses in autonomic ganglia.
(05 Mar 2000)
neuromuscular blocking agent A group of drugs that prevent motor nerve endings from exciting skeletal muscle. They act either by competing for the neurotransmitter, acetylcholine, (like D-tubocurarine, mivacurium and pancuronium), or by first stimulating the postjunctional muscle membrane and subsequently desensitizing the muscle endplates to the acetylcholine (like succinylcholine or decamethonium); used in surgery to produce paralysis and facilitate manipulation of muscles.
(05 Mar 2000)
nondepolarising neuromuscular blocking agent A compound that paralyzes skeletal muscle primarily by inhibiting transmission of nerve impulses at the neuromuscular junction rather than by affecting the membrane potention of motor endplate or muscle fibres.
(05 Mar 2000)
calcium channel <physiology> A membrane channel that is specific for calcium. It is a voltage-dependent cell membrane glycoproteins selectively permeable to calcium ions. They are categorised as l, t, n, or p types based on the activation and inactivation kinetics, ion specificity, and sensitivity to drugs and toxins.
(12 May 2002)
calcium channel agonist <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues.
This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
(12 Dec 1998)
calcium channel antagonist <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
calcium channel-blocker <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
ryanodine receptor calcium release channel Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blocking
    ¿À¸®´ë(Æ´À» ¸Þ¿ì´Â ³ª¹µÁ¶°¢);ºí·ÎÅ·;ÀúÁö Çö»ó(¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº »ó³ä¿¡ ÀÇÇÑ ¿¬»ó Áß´Ü);(¹è¿ìÀÇ)¿¬Ãâ;ºí·ÎÅ·Çϱâ
  • calcium
    Ä®½·
  • calcium
    Ä®½·(±Ý¼Ó¿ø¼Ò,±âÈ£ Ca,¹øÈ£ 20)
  • calcium arsenate
    ºñ»êÄ®½·(»ìÃæÁ¦)
  • calcium carbide
    źȭĮ½·
  • calcium carbonate
    ź»êÄ®½·
  • calcium chloride
    ¿°È­Ä®½·
  • calcium hydroxide
    ¼ö»êÈ­Ä®½·;¼Ò¼®È¸
  • calcium light
    Ä®½·±¤(limelight)
  • calcium oxide
    »êÈ­Ä®½·;»ý¼®È¸
  • calcium phosphate
    ÀλêÄ®½·
  • channel
    ¼ö·Î
  • Channel Islands
    ÇØÇùÁ¦µµ(ÇÁ¶û½º ºÏ¼­ºÎÀÇ ¿µ·ÉÀÇ ¼¶)
  • English Channel
    ¿µ±¹ ÇØÇù
  • North Channel
    ³ë½º ÇØÇùÄÚÆ²·£µå¿Í ºÏ¾ÆÀÏ·£µå »çÀÌ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á